Arcutis Biotherapeutics Inc. (ARQT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average
From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now
Arcutis Biotherapeutics (ARQT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average
Arcutis Biotherapeutics, Inc. (ARQT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ARQT broke through the 20-day moving average, which suggests a short-term bullish trend.
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Following the successful product launch of Zoryve, Arcutis Biotherapeutics has returned an impressive +200% year-to-date. Recent Q3 earnings impressed, with a blistering 452% year-over-year and 45% quarter-over-quarter revenue growth. The growth trend seems poised to continue, with an expanding total patient opportunity and the industry trending away from topical steroids, which present lower efficacy and higher risk.
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?
The consensus price target hints at a 70.3% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Investor Relations Frank Watanabe - President and CEO Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Seamus Fernandez - Guggenheim Securities Uy Ear - Mizuho Serge Belanger - Needham & Co. Kambiz Yazdi - Jefferies Operator Good day, and welcome to the Arcutis Biotherapeutics 2024 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates
Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.73 per share a year ago.
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
Arcutis Biotherapeutics, Inc. is a biotech company based in California that markets two dermatological products, ZORYVE cream and foam, containing roflumilast, a PDE4 inhibitor. Despite initial struggles post-IPO, Arcutis has seen a significant increase in revenues and a narrowing of losses in Q2 2024, with new product approvals and collaborations. Analysts predict strong growth potential for ZORYVE, but competition in the dermatological market poses a challenge for Arcutis to maintain and grow market share.
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2024 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Latha Vairavan - VP, Finance and Head of IR Frank Watanabe - President & CEO Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - CFO Conference Call Participants Vikram Purohit - Morgan Stanley Tyler Van Buren - TD Cowen Seamus Fernandez - Guggenheim Securities Uy Ear - Mizuho Securities Serge Belanger - Needham Chris Shibutani - Goldman Sachs Operator Hello, and thank you for standing by. Welcome to Arcutis Biotherapeutics Q2 2024 Earnings Call.
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates
Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $1.16 per share a year ago.
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
